孙学明, 吴慧, 卢晓旭, 黄蓉. 同期放化疗对比单纯放疗治疗非高发区T1~2N1M0期鼻咽癌远期疗效观察[J]. 中国肿瘤临床, 2020, 47(5): 241-244. DOI: 10.3969/j.issn.1000-8179.2020.05.011
引用本文: 孙学明, 吴慧, 卢晓旭, 黄蓉. 同期放化疗对比单纯放疗治疗非高发区T1~2N1M0期鼻咽癌远期疗效观察[J]. 中国肿瘤临床, 2020, 47(5): 241-244. DOI: 10.3969/j.issn.1000-8179.2020.05.011
shu
Xueming Sun, Hui Wu, Xiaoxu Lu, Rong Hong. Comparison of efficacy of concurrent chemoradiotherapy and intensity-modulated radiotherapy alone for patients with stage T1-2N1M0 nasopharyngeal carcinoma in an unendemic area[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 47(5): 241-244. DOI: 10.3969/j.issn.1000-8179.2020.05.011
Citation: Xueming Sun, Hui Wu, Xiaoxu Lu, Rong Hong. Comparison of efficacy of concurrent chemoradiotherapy and intensity-modulated radiotherapy alone for patients with stage T1-2N1M0 nasopharyngeal carcinoma in an unendemic area[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 47(5): 241-244. DOI: 10.3969/j.issn.1000-8179.2020.05.011
shu

同期放化疗对比单纯放疗治疗非高发区T1~2N1M0期鼻咽癌远期疗效观察

Comparison of efficacy of concurrent chemoradiotherapy and intensity-modulated radiotherapy alone for patients with stage T1-2N1M0 nasopharyngeal carcinoma in an unendemic area

    摘要
  • 摘要:
      目的  回顾性配对分析以适形调强放疗为基础的不同治疗模式对非高发区T1~2N1M0期鼻咽癌患者预后的影响。
      方法  回顾性分析2010年1月至2015年12月河南省肿瘤医院初治的行根治性放疗的T1~2N1M0期鼻咽癌患者，筛选出51对患者（单纯放疗组和同期放化疗组各51例）进行配对分析。比较两组患者各项生存率及急性不良反应。
      结果  全组5年总生存率、无局部复发生存率、无区域复发生存率、无远处转移生存率分别为94.1%、93.6%、96.7%、90.9%。单纯放疗组与同期放化疗组相比，5年总生存率（95.9% vs.92.2%，P=0.894）、无局部复发生存率（94.1% vs.93.3%，P=0.976）、无区域复发生存率（95.8% vs.97.6%，P=0.572）、无远处转移生存率（91.4% vs.90.2%，P=0.716），差异均无统计学意义。急性不良反应方面，与单纯放疗组相比，同期放化疗组呕吐、中性粒细胞减少、白细胞减少、血红蛋白减少和黏膜炎的发生率显著升高。
      结论  对于T1~2N1M0期鼻咽癌患者，同期化疗的加入并未明显改善患者预后，且急性不良反应增加。

     

    Abstract:
      Objective  To compare the efficacy of intensity-modulated radiotherapy (IMRT) alone and concurrent chemoradiotherapy (CCRT) for patients with stage T1-2N1M0 nasopharyngeal carcinoma (NPC) in an unendemic area.
      Methods  Between January 2010 and December 2015, 102 patients with stage T1-2N1M0 NPC who underwent radical radiotherapy were selected for a pair analysis. Survival rates and acute adverse reactions were compared between the two groups.
      Results  The 5-year overall survival (OS), local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), and distant metastasis-free survival (DMFS) rates were 94.1%, 93.6%, 96.7%, and 90.9%, respectively. Compared with IMRT alone, CCRT failed to significantly improve the 5-year OS (95.9% vs. 92.2%, P=0.894), LRFS (94.1% vs. 93.3%, P=0.976), RRFS (95.8% vs. 97.6%, P=0.572) and DMFS (91.4% vs. 90.2%, P=0.716)rates. The incidence rates of vomiting, neutropenia, leukopenia, decreased hemoglobin levels, and mucositis were significantly higher in the CCRT group than in the IMRT-alone group.
      Conclusions  For patients with stage T1-2N0M0 disease, CCRT failed to improve the prognosis, but increased the incidence rates of acute toxicities.

     

    • HTML全文
    • 参考文献(15)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回